ARID1A and non-small cell lung carcinoma: A similar negative impact was observed in patients with EGFR‐mutated NSCLC treated with osimertinib or second‐generation EGFR inhibitors, in which ARID1A mutations were observed more frequently in tumors with TP53 alterations [46].